Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
Driven by its strategic goal to advance equity in the U.S. healthcare innovation sector, the American Medical Association (AMA) recently announced an initiative that supports leading industry stakeholders in committing to equitable health innovation opportunities targeted to improving health outcomes in historically marginalized communities. #Healthdisparities 

Bivalirudin bests heparin for treating heart attack patients undergoing PCI

The findings were presented Wednesday, Oct. 14, during TCT Connect 2020. 

October 14, 2020
COVID

Confirmed: Key heart medications safe to use for COVID-19 patients

The BRACE CORONA trial focused on the safety of taking angiotensin-converting enzyme inhibitors and angiotensin receptor blockers when hospitalized with COVID-19.

September 1, 2020
""

Empagliflozin reduces risk of cardiovascular death, hospitalization among heart failure patients

The EMPEROR-Reduced trial included data from more than 3,700 adult patients with HF and a left ventricular ejection fraction of 40% or less.

August 31, 2020

THALES trial results: Can ticagrelor and aspirin reduce stroke rates for at-risk patients?

Results of the trial, which included more than 11,000 patients, were published in the New England Journal of Medicine.

July 16, 2020
The American College of Cardiology and American Heart Association have collaborated on a new update to the much-discussed 2021 chest pain guidelines. The American College of Emergency Physicians and Society for Cardiac Angiography and Interventions also contributed to the document.

'A missed opportunity': Statin use low among patients with peripheral artery disease

Researchers tracked statin use among patients with peripheral artery disease, cerebrovascular disease and coronary heart disease.

July 13, 2020

Specialists share experience prescribing a historically expensive cardiovascular medication

Tafamidis received FDA approval in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It has a list price of $225,000 per year.

June 18, 2020

Machine learning predicts drug cardiotoxicity

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

June 10, 2020
physician payment concept image

America’s most expensive CV drug needs a 93% price cut

A 92.6% reduction in the list price of tafamidis—an effective but ultimately unaffordable drug designed to treat transthyretin amyloid cardiomyopathy—would be required to make the medication accessible to the average heart patient, researchers reported in Circulation Feb. 12.

February 14, 2020
Displaying 217 - 224 of 238

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup